3/19
07:21 am
acrv
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Medium
Report
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
3/17
06:16 pm
acrv
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors [Yahoo! Finance]
Low
Report
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors [Yahoo! Finance]
3/17
05:54 pm
acrv
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
Low
Report
Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors
3/3
01:47 pm
acrv
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why [Yahoo! Finance]
Medium
Report
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why [Yahoo! Finance]
3/2
09:02 pm
acrv
Acrivon Therapeutics (ACRV) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
High
Report
Acrivon Therapeutics (ACRV) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/1
01:10 am
acrv
Low
Report
2/27
12:00 pm
acrv
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer [Yahoo! Finance]
Medium
Report
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer [Yahoo! Finance]
2/24
08:33 am
acrv
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Low
Report
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/24
08:00 am
acrv
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Neutral
Report
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
2/23
08:00 am
acrv
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
Low
Report
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
2/21
02:04 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
Low
Report
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
2/18
08:00 am
acrv
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
Low
Report
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
1/28
09:15 am
acrv
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
Low
Report
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
1/23
08:11 am
acrv
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
Low
Report
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
1/18
08:46 am
acrv
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares [Yahoo! Finance]
Low
Report
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares [Yahoo! Finance]
1/10
01:07 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at
Wall St
Medium
Report
Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at
Wall St
1/9
07:18 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Acrivon Therapeutics (NASDAQ:ACRV) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/8
07:30 am
acrv
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
High
Report
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
1/6
07:30 am
acrv
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
High
Report
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
12/30
04:09 pm
acrv
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/23
04:09 pm
acrv
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/21
01:08 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
Medium
Report
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre